Screening for GPCR ligands using surface plasmon resonance

ACS Medicinal Chemistry Letters

Volumn 2, Issue 7, 2011, Pages 549-554

  Navratilova, Iva ^a   Besnard, Jérémy ^a   Hopkins, Andrew L ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

allosteric; CCR5; fragments; G protein coupled receptors; Surface plasmon resonance

Indexed keywords

CHEMOKINE RECEPTOR CCR5; G PROTEIN COUPLED RECEPTOR;

ALLOSTERISM; ARTICLE; BINDING SITE; LIGAND BINDING; ORTHOGONAL ROTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE;

EID: 79960398015     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml2000017     Document Type: Article

References (21)

1. Kenakin, T. Allosteric Theory: Taking Therapeutic Advantage of the Malleable Nature of GPCRs Curr. Neuropharmacol. 2007, 5, 149-156 (Pubitemid 351863856)
2. Keov, P.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of G protein-coupled receptors: A pharmacological perspective Neuropharmacology 2011, 60 (1) 24-35
3. Watson, C.; Jenkinson, S.; Kazmierski, W.; Kenakin, T. The CCR5 Receptor-based mechanism of action of 873140, a potent allosteric non-competitive HIV entry-inhibitor Mol. Pharmacol. 2005, 67, 1268-1282 (Pubitemid 40410427)
4. Mansfield, R.; Able, S.; Griffin, P.; Irvine, B.; James, I.; Macartney, M.; Miller, K.; Mills, J.; Napier, C.; Navratilova, I.; Perros, M.; Rickett, G.; Root, H.; van der Ryst, E.; Westby, M.; Dorr, P. CCR5 Pharmacology Methodologies and Associated Applications Methods Enzymol. 2009, 460, 17-55
5. Muniz-Medina, V. M.; Jones, S.; Maglich, J. M.; Galardi, C.; Hollingsworth, R. E.; Karzmierski, W. M.; Ferris, R. G.; Edelstein, M. P.; Chiswell, K. E.; Kenakin, T. P. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalisation: Is allosteric funtional selectivty a valuable therapeutic property? Mol. Pharmacol. 2009, 75 (3) 490-501
6. Dorr, P.; Westby, M.; Dobbs, S.; Griffin, P.; Irvine, B.; Macartney, M.; Mori, J.; Rickett, G.; Smith-Burchnell, C.; Napier, C.; Webster, R.; Armour, D.; Price, D.; Stammen, B.; Wood, A.; Perros, M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity Antimicrob. Agents Chemother. 2005, 49 (11) 4721-4732 (Pubitemid 41552605)
7. Urban, J. D.; Clarke, W. P.; von Zastrow, M.; Nichols, D. E.; Kobilka, B.; Weinstein, H.; Javitch, J. A.; Roth, B. L.; Christopoulos, A.; Sexton, P. M.; Miller, K. J.; Spedding, M.; Mailman, R. B. Functional selectivity and classical concepts of quantitative pharmacology J. Pharmacol. Exp. Ther. 2007, 320 (1) 1-13 (Pubitemid 46025713)
8. Galandrin, S.; Oligny-Longpré, G.; Bouvier, M. The evasive nature of drug efficacy: Implications for drug discovery Trends Pharmacol. Sci. 2007, 28 (8) 423-430 (Pubitemid 47087968)
9. Lane, J. R.; Powney, B.; Wise, A.; Rees, S.; Milligan, G. Protean agonism at the dopamine D2 receptor: (S)-3-(3-hydroxyphenyl)- N -propylpiperidine is an agonist for activation of Go1 but an antagonist/inverse agonist for Gi1,Gi2, and Gi3 Mol. Pharmacol. 2007, 71 (5) 1349-1359 (Pubitemid 46658688)
10. Andrews, G.; Jones, C.; Wreggett, K. A. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5 Mol. Pharmacol. 2008, 73 (3) 855-867 (Pubitemid 351397890)
11. Nicholls, D. J.; Tomkinson, N. P.; Wiley, K. E.; Brammall, A.; Bowers, L.; Grahames, C.; Gaw, A.; Meghani, P.; Shelton, P.; Wright, T. J.; Mallinder, P. R. Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2 Mol. Pharmacol. 2008, 74 (5) 1193-1202
12. Navratilova, I.; Sodroski, J.; Myszka, D. G. Solubilization, stabilization, and purification of chemokine receptors using biosensor technology Anal. Biochem. 2005, 339 (2) 271-281 (Pubitemid 40395285)
13. Navratilova, I.; Pancera, M.; Wyatt, R. T.; Myszka, D. G. A biosensor-based approach toward purification and crystallization of G protein-coupled receptors Anal. Biochem. 2006, 353 (2) 278-283 (Pubitemid 43775440)
14. Navratilova, I.; Dioszegi, M.; Myszka, D. G. Analyzing ligand and small molecule binding activity of solubilized GPCRs using biosensor technology Anal. Biochem. 2006, 355 (1) 132-139 (Pubitemid 44041399)
15. Rich, R. L.; Errey, J.; Marshall, F.; Myszka, D. G. Biacore analysis with stabilized G-protein-coupled receptors. Anal. Biochem. 2010, in press.
16. Robertson, N.; Jazayeri, A.; Errey, J.; Baig, A.; Hurrell, E.; Zhukov, A.; Langmead, C. J.; Weir, M.; Marshall, F. H. The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery Neuropharmacology 2011, 60 (1) 36-44
17. Haworth, B.; Lin, H.; Fidock, M.; Dorr, P.; Strange, P. G. Allosteric effects of antagonists on signalling by the chemokine receptor CCR5 Biochem. Pharmacol. 2007, 74 (6) 891-897 (Pubitemid 47212080)
18. Orita, M.; Ohno, K.; Niimi, T. Two 'Golden Ratio' indices in fragment-based drug discovery Drug Discovery Today 2009, 14 (5-6) 321-328
19. Vaidehi, N.; Schlyer, S.; Trabanino, R. J.; Floriano, W. B.; Abrol, R.; Sharma, S.; Kochanny, M.; Koovakat, S.; Dunning, L.; Liang, M.; Fox, J. M.; de Mendonça, F. L.; Pease, J. E.; Goddard, W. A. r.; Horuk, R. Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation J. Biol. Chem. 2006, 281 (37) 27613-27620 (Pubitemid 44401786)
20. Wise, E. L.; Duchesnes, C.; da Fonseca, P. C.; Allen, R. A.; Williams, T. J.; Pease, J. E. Small Molecule Receptor Agonists and Antagonists of CCR3 Provide Insight into Mechanisms of Chemokine Receptor Activation J. Biol. Chem. 2007, 282 (38) 27935-27943 (Pubitemid 47529544)
21. Kondru, R.; Zhang, J.; Ji, C.; Mirzadegan, T.; Rotstein, D.; Sankuratri, S.; Dioszegi, M. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists Mol. Pharmacol. 2008, 73 (3) 789-800 (Pubitemid 351397884)